RWM
ALNY icon

Rialto Wealth Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Rialto Wealth Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.27K Buy
27
+22
+440% +$6.63K ﹤0.01% 575
2026
Q1 		$1.66K Buy
5
+2
+67% +$681 ﹤0.01% 929
2025
Q4 		$1.19K Hold
3
– – ﹤0.01% 935
2025
Q3 		$1.37K Hold
3
– – ﹤0.01% 804
2025
Q2 		$979 Buy
+3
New +$830 ﹤0.01% 881

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rialto Wealth Management's ALNY Position: Q2 2026 in Review

Rialto Wealth Management increased its Alnylam Pharmaceuticals (ALNY) stake by 440% in Q2 2026, buying an estimated $6.63K and bringing the position to 27 shares worth $8.27K. The position accounts for ﹤0.01% of the portfolio, ranked #575.

Rialto Wealth Management first reported a position in ALNY in Q2 2025 and has held it in 5 quarters since. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Rialto Wealth Management held 27 shares of Alnylam Pharmaceuticals worth $8.27K as of Q2 2026.
  • Rialto Wealth Management bought 22 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $6.63K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Rialto Wealth Management's portfolio in Q2 2026, its #575 holding.
  • Rialto Wealth Management first reported a position in Alnylam Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Rialto Wealth Management's 13F filing for Q2 2026, filed 11 Aug 2026.